Clinical Trial

Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to test the effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation. The main questions it aims to answer are: • If Dapagliflozin will reduce the recurrence of all atrial tachyarrhythmias \[atrial fibrillation (AF), atrial flutter (AFL) and atrial tachycardia (AT)\] greater than 30 seconds during one-year follow-up after catheter ablation. Participants will receive Dapagliflozin (FORXIGA) 10 milligram (mg) once a day (QD) for 3 months after catheter ablation of atrial fibrillation. Researchers will compare patients who receive usual care to see if Dapagliflozin will reduce the recurrence of all atrial tachyarrhythmias (AF/AFL/AT) during one-year follow-up after catheter ablation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-26.
Status change: Recruiting → Active, Not Recruiting 2023-12-19
Trial Details
NCT Number NCT06111443
Lead Sponsor Chang Gung Memorial Hospital
Conditions Atrial Fibrillation Recurrent, Catheter Ablation
Enrollment 196 participants
Start Date 2023-12-01
Primary Completion 2026-11-30 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2023-12-21